Motif Bio PLC Appointments to Scientific Advisory Board (6645E)
10 May 2017 - 4:00PM
UK Regulatory
TIDMMTFB
RNS Number : 6645E
Motif Bio PLC
10 May 2017
Motif Bio plc
("Motif Bio" or the "Company")
Motif Bio Appoints Scientific Opinion Leaders to Advisory
Board
Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical
company specialising in developing novel antibiotics, today
announced the appointment of Dr.Thomas Lodise, Dr.Thomas Holland
and Dr.William O'Riordan to the Clinical Advisory Board.
The three new advisory board members are medical and scientific
leaders in their fields:
Thomas Lodise, Pharm.D., Ph.D. is a Professor at Albany College
of Pharmacy and Health Sciences, Albany, New York and an infectious
diseases clinical pharmacy specialist at the Stratton VA Medical
Center, Albany, New York. His specific research objectives are to
develop "personalised" patient care strategies that improve
outcomes; reduce the likelihood of drug-induced toxicities;
minimize the emergence of antibiotic resistant infections; and
reduce healthcare costs. He has published over 110 peer-reviewed
articles and is an editorial board member for Antimicrobial Agents
and Chemotherapy, Pharmacotherapy, and Diagnostic Microbiology and
Infectious Diseases. He is the current chair of the PK Special
Emphasis Panel for the Antibacterial Resistance Leadership Group
(ARLG), an initiative funded by the National Institute of Allergy
and Infectious Diseases (NIAID) of the National Institutes of
Health (NIH).
Thomas L. Holland, MD, MSc-GH is an Assistant Professor at Duke
University School of Medicine. Board certified in infectious
disease, Dr Holland has held a number of clinical positions at Duke
University School of Medicine and is currently Assistant Professor
in the Department of Infectious Diseases. With over 30
publications, Dr Holland is an expert in antibacterial resistance
with a focus on Gram-positive bacteria and is a member of ARLG.
William D. O'Riordan, MD is the founder and CEO of eStudy Sites,
one of the pre-eminent network of clinical trial sites in the U.S.
He is certified with the American Board of Emergency Medicine and
is the lead investigator at the Chula Vista Research Site in
California. Dr. O'Riordan has held a number of clinical positions
at the UCLA (University of California, Los Angeles) Medical Center
and works at the Department of Emergency Medicine at the Sharp
Chula Vista Medical Center. As a clinical trial Investigator at the
eStudy Site at the Chula Vista Research Site, he has overseen
numerous clinical trials with antibacterial agents at all stages of
clinical development.
Dr. David Huang, CMO of Motif Bio commented: "We are delighted
to welcome these three outstanding scientific leaders to our
Clinical Advisory Board. Each of them brings specific expertise
that will be invaluable as we develop and prepare to commercialise
iclaprim for patients with serious and life-threatening
infections."
For further information please contact:
Motif Bio plc info@motifbio.com
Graham Lumsden (Chief
Executive Officer)
Peel Hunt LLP (NOMAD
& BROKER)
Dr. Christopher Golden/
Oliver Jackson +44 (0)20 7418 8900
Northland Capital Partners
Limited (BROKER)
Patrick Claridge/ David
Hignell
John Howes/ Rob Rees
(Broking) +44 (0)20 3861 6625
Walbrook PR Ltd. (FINANCIAL +44 (0)20 7933 8780 or
PR & IR) motifbio@walbrookpr.com
Paul McManus Mob: +44 (0)7980 541 893
Mike Wort Mob: +44 (0)7900 608 002
MC Services AG (EUROPEAN
IR)
Raimund Gabriel +49 (0)89 210 2280
About Motif Bio plc www.motifbio.com
Notes to Editors:
Motif Bio is a clinical-stage biopharmaceutical company, engaged
in the research and development of novel antibiotics designed to be
effective against serious and life-threatening infections in
hospitalised patients caused by multi-drug resistant bacteria. Our
lead product candidate, iclaprim, is being developed for the
treatment of acute bacterial skin and skin structure infections
(ABSSSI) and hospital acquired bacterial pneumonia (HABP),
including ventilator associated bacterial pneumonia (VABP),
infections often caused by MRSA (methicillin resistant
Staphylococcus aureus). Having completed the REVIVE-1 trial,
patients are currently being enrolled and dosed in a second global
Phase 3 clinical trial (REVIVE-2) with an intravenous formulation
of iclaprim, for the treatment of ABSSSI. Data readout for REVIVE-2
is expected in the second half of 2017.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCLLFFAEEIAIID
(END) Dow Jones Newswires
May 10, 2017 02:00 ET (06:00 GMT)
Motif Bio (LSE:MTFB)
Historical Stock Chart
From Apr 2024 to May 2024
Motif Bio (LSE:MTFB)
Historical Stock Chart
From May 2023 to May 2024